ArticlePediatric nephrology (Berlin, Germany)1993
Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial.Clinical journal of the American Society of Nephrology : CJASN · 2014Trial
- Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- Decreased cyclosporine exposure during the remission of nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2007Trial
- Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis.Pediatric nephrology (Berlin, Germany) · 2003Trial
- Steroid-resistant, cyclosporine-responsive, relapsing nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 1995Trial
- Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: Effects of body weight and spirolactone administration.Experimental and therapeutic medicine · 2019Article
- Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.Clinical and experimental nephrology · 2010Article
- Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2006Article
- Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience.Postgraduate medical journal · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the effect of 18-month ciclosporin (CS) treatment in 19 children with steroid-dependent frequently relapsing nephrotic syndrome. CS was started at 3-5 mg/kg per day after remission with steroid therapy, was adjusted to maintain a trough blood level of between 200 and 600 ng/ml and was administered for 6 months (high-dose CS). Then, the dosage of CS was decreased and 2.5 mg/kg per day was administered for the subsequent 12 months (low-dose CS). Only 2 patients had relapses during the initial 6 months of CS therapy. Eight patients had infrequent relapses, 4 had frequent relapses and 7 had no relapses during the 12 months of low-dose CS. Not only did continuation of CS at a lower dosage decrease the relapse rate, it also reduced steroid toxicity, allowed increased growth in 16 of the 19 patients and also decreased obesity scores in 12 of these patients. All of the side-effects that occurred during the 18-month period of CS treatment were reversible and none was serious enough to necessitate discontinuation of therapy. Our 18-month CS treatment was helpful in preventing relapses and reducing steroid toxicity in children with steroid-dependent frequently relapsing nephrotic syndrome.
Indexed as
Identifiers
8518091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.